Mar 9, 2017 by Brian FeroldiBetter Buy: MannKind Corp. vs. DexcomBoth of these companies are focused on diabetes, but which is the better choice for investors today?
Mar 9, 2017 by Brian Feroldi2 Dividend Stocks to Stay Away From -- and 1 Worth BuyingThese three companies offer up huge dividend yields, but only one is worthy of your capital.
Mar 8, 2017 by Brian FeroldiHere's Why Natera, Inc. Is Tumbling TodayShares fall hard in response to the release of a less than stellar earnings report.
Mar 8, 2017 by Brian Feroldi3 Stocks That Have Been Cut in Half in the Last 6 MonthsIts been a rough half-year to be an investor in Under Armour, StonMor Partners, and Intra-Cellular Therapies. Are these beaten-down stocks bargains, or could there be more pain ahead?
Mar 6, 2017 by Brian FeroldiHere's Why Novan Inc. Is Rising TodayThe announcement that an important clinical program is moving forward has put investors in a good mood.
Mar 6, 2017 by Brian FeroldiThe Probable Reason Behind Vertex Pharmaceuticals 5% Jump in FebruaryShares picked up steam during the month. Was this the simple reason behind the rally?
Mar 5, 2017 by Brian Feroldi10 Highest Dividend-Yielding StocksThese 10 companies offer big payouts -- but are any of them actually worth buying?
Mar 4, 2017 by Brian Feroldi, Anders Bylund, and Cory Renauer3 Popular Stocks Hedge Fund Tycoons Are DitchingA handful of big money managers have been selling off their stakes in NXP Semiconductors, Bank of America, and Barrick Gold recently. Read on to find out why.
Mar 3, 2017 by Brian Feroldi3 Tax Breaks Families Won't Want to MissIf you have children, these three favorable tax provisions could save you thousands.
Mar 3, 2017 by Brian FeroldiHere's Why Pfizer Rallied 7.7% in FebruaryIt was a busy month for the pharma giant. Here's a look at the key developments that caused its share price to rally.
Mar 3, 2017 by Brian Feroldi2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February JumpHere's a closer look at why this rare-disease biotech stock rallied last month.
Mar 3, 2017 by Brian FeroldiHere's Why Amgen Stock Rose 10.5% in FebruaryIt was an event-filled month for the biotech giant. Here's a look at the key headlines that drove its share price higher.
Mar 3, 2017 by Brian Feroldi70 or Older? 3 Stocks You Should Consider BuyingHere's why Pfizer, Ecolab, and NextEra Energy could be great stocks for investors in their golden years.
Mar 2, 2017 by Brian FeroldiWhy PTC Therapeutics Is Plunging TodayShares drop after the company reports phase 3 trial results that missed the mark.
Mar 1, 2017 by Brian FeroldiDiplomat Pharmacy's Shares Are Soaring Today -- But Why?Despite posting disappointing fourth-quarter results and issuing downbeat guidance, the company's shares still popped.
Feb 28, 2017 by Brian Feroldi, Dan Caplinger, Travis Hoium, and Matt DiLallo4 Stocks to Own for the Next DecadeHere's why our team of Fools thinks that Brookfield Renewable Partners, Oracle, 8point3 Energy Partners, and Facebook are all built to last.
Feb 28, 2017 by Brian Feroldi, Jason Hall, and Timothy GreenBillionaires Love These 3 Stocks -- but Should You?A few famous investors have amassed big positions in Apple, Sears Holdings, and Antero Resources, but should retail investors follow suit?
Feb 27, 2017 by Brian FeroldiWhy ViewRay Is Soaring TodayShares jumped after the company received the thumbs-up from the FDA and preannounced upbeat financial results.
Feb 27, 2017 by Brian Feroldi, Chuck Saletta, Tyler Crowe, Jason Hall, and Jordan WathenThe 5 Best Dividend Stocks for Beginning InvestorsAre you a new investor that wants to focus on income? If so, you should consider giving these high-yield dividend-paying stocks a close look.
Feb 27, 2017 by Brian FeroldiWhy La Jolla Pharmaceutical Company Shares Are SkyrocketingThe release of upbeat data from an important phase 3 trial has investors cheering.
